These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 2797340)

  • 21. Treatment of hemodialysis bone disease with 24,25-(OH)2D3 and 1,25-(OH)2D3 alone or in combination.
    Dunstan CR; Hills E; Norman AW; Bishop JE; Mayer E; Wong SY; Eade Y; Johnson JR; George CR; Collett P
    Miner Electrolyte Metab; 1985; 11(6):358-68. PubMed ID: 3877862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Combined therapy with calcitonin and high doses of active vitamin D3 metabolites in uremic hyperparathyroidism].
    Matuszkiewicz-Rowińska J; Niemczyk S; Puka J; Sawicki A; Switalski M; Tałałaj M; Pacocha E; Marusza W; Ostrowski K
    Pol Arch Med Wewn; 1996 Jul; 96(1):23-31. PubMed ID: 8966142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
    Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of pulse therapy using 1 alpha(OH)D on secondary hyperparathyroidism in patients on maintenance hemodialysis].
    Yoshida K; Hirayama A; Tanaka N; Yasukawa M; Saka M; Kaneko Y; Maruyama Y; Motomiya Y; Ozono S; Hirao Y
    Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1117-23. PubMed ID: 2287104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH)3.
    Demontis R; Leflon A; Fournier A; Tahiri Y; Herve M; Moriniere P; Abdull-Massih Z; Atik H; Belbrik S; Renaud H
    Clin Nephrol; 1986 Sep; 26(3):146-9. PubMed ID: 3769230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute effect of dialysate calcium concentration and intravenous vitamin D3 on the secretion of parathyroid hormone in hemodialysis patients.
    Saha H; Pietilä K; Mustonen J; Pasternack A; Mörsky P
    Clin Nephrol; 1992 Sep; 38(3):145-8. PubMed ID: 1395167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3.
    Djukanović L; Pejanović S; Dragojlović Z; Stosović M
    Ren Fail; 1994 Nov; 16(6):715-23. PubMed ID: 7899583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
    Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
    Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol.
    Shigematsu T; Kawaguchi Y; Unemura S; Yamamoto H; Momose M; Yokoyama K; Wakabayashi Y; Ikeda M; Hasegawa T; Sakai O
    Intern Med; 1993 Sep; 32(9):695-701. PubMed ID: 8142673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of serum parathyroid hormone levels by intravenous alphacalcidol in uremic patients on maintenance hemodialysis. A pilot study.
    Lind L; Wengle B; Wide L; Wrege U; Ljunghall S
    Nephron; 1988; 48(4):296-9. PubMed ID: 3362275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
    Mortensen BM; Gautvik KM; Gordeladze JO
    Biosci Rep; 1993 Feb; 13(1):27-39. PubMed ID: 8392394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy.
    Rapoport J; Mostoslavski M; Ben-David A; Knecht A; Blau A; Arad J; Zlotnik M; Chaimovitz C
    Nephron; 1996; 72(2):150-4. PubMed ID: 8684518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D3 in patients on maintenance haemodialysis.
    Rassoul Z; Mousa D; Rehman MA; Abdalla AH; Hawas F; Popovich W; Gaisoum M; al-Sulaiman M; Al-Khader A
    Am J Nephrol; 1995; 15(6):507-11. PubMed ID: 8546173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure.
    Pitts TO; Piraino BH; Mitro R; Chen TC; Segre GV; Greenberg A; Puschett JB
    J Clin Endocrinol Metab; 1988 Nov; 67(5):876-81. PubMed ID: 3182962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients.
    Alghareeb A; Sabry A; Bawadekji H; Alsaran K
    Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
    Perez-Mijares R; Gomez-Fernandez P; Almaraz-Jimenez M; Ramos-Diaz M; Rivero-Bohorquez J
    Am J Nephrol; 1993; 13(2):149-54. PubMed ID: 8342582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin D Metabolites and Their Association with Calcium, Phosphorus, and PTH Concentrations, Severity of Illness, and Mortality in Hospitalized Equine Neonates.
    Kamr AM; Dembek KA; Reed SM; Slovis NM; Zaghawa AA; Rosol TJ; Toribio RE
    PLoS One; 2015; 10(6):e0127684. PubMed ID: 26046642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Administration of calcium carbonate with adequate doses of vitamin D metabolite to patients on hemodialysis improves mild secondary hyperparathyroidism.
    Okada K; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1990 Aug; 32(8):899-903. PubMed ID: 2250406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating 1,25-dihydroxycholecalciferol after intravenous injections of 1 alpha-hydroxycholecalciferol in patients on regular haemodialysis.
    Papapoulos SE; vd Berg H; Frölich M; Valentijn RM
    Nephrol Dial Transplant; 1988; 3(5):647-50. PubMed ID: 3146722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.